Infections · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
Inhaled corticosteroids plus standard care showed no clear difference in infections compared with standard care (with or without placebo) (low certainty).
1 finding from 1 review
OutcomesTime frame of absolute effects · hospitalised people with confirmed SARS‐CoV‐2 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality (up to day 28) · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
All‐cause mortality (up to day 60) · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
Improvement in clinical status: discharged alive or hospitalised, but no longer requiring ongoing medical care (up to day 28) · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
Clinical worsening: new need for invasive mechanical ventilation or death · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
Adverse events: all grades · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
Serious adverse events · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
Secondary infection · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
Clinical improvement D28
Anakinra showed no clear difference in clinical improvement D28 compared with standard care/placebo (moderate certainty).
1 finding from 1 review
Time to WHO Clinical Progression Score of level 7 or above
Anakinra may leads to lower time to WHO Clinical Progression Score of level 7 or above compared with standard care/placebo (low certainty).
1 finding from 1 review
Time to death
Anakinra showed no clear difference in time to death compared with standard care/placebo (low certainty).
1 finding from 1 review
Clinical improvement D28
Canakinumab showed no clear difference in clinical improvement D28 compared with standard care/placebo (moderate certainty).
1 finding from 1 review
Clinical improvement D60 or above
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
WHO progression score (level 7 or above) D28
Canakinumab showed no clear difference in WHO Clinical Progression Score of level 7 or above D28 compared with standard care/placebo (low certainty).
1 finding from 1 review
WHO Clinical Progression Score of level 7 or above D60 or above
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality D28
Canakinumab showed no clear difference in all‐cause mortality D28 compared with standard care/placebo (low certainty).
1 finding from 1 review
All‐cause mortality D60 or more
It is very uncertain whether canakinumab changes all‐cause mortality D60 or above compared with standard care/placebo (very low certainty).
1 finding from 1 review
Adverse events
Canakinumab showed no clear difference in adverse events compared with standard care/placebo (moderate certainty).
1 finding from 1 review
Serious adverse eventsÂ
Canakinumab showed no clear difference in serious adverse events compared with standard care/placebo (low certainty).
1 finding from 1 review